Biogen, AbbVie withdraw MS drug Zinbryta globally, halt trials

Biogen Inc. (NASDAQ:BIIB) and partner AbbVie Inc. (NYSE:ABBV) will withdraw multiple sclerosis drug Zinbryta daclizumab globally from the market following eight European cases of inflammatory brain disorders, including encephalitis and meningoencephalitis. The partners are also halting all clinical trials and EMA has begun a review of the drug.

Zinbryta is marketed in the U.S., EU, Switzerland, Canada and Australia to treat relapsing forms of MS. More than 8,000 patients have been treated with the drug worldwide, according to the EMA...